Evommune, Inc. has filed an amendment to its Schedule 13D, revealing a dilution in the beneficial ownership of its common stock by RA Capital Management and its affiliates. This event is significant as it reflects ongoing changes in shareholder dynamics within the pharmaceutical preparations sector.
According to the filing dated November 10, 2026, the reporting persons, which include RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively hold approximately 8.5% of Evommune's common stock. The filing states, "This Amendment No. 2 is being filed to report the dilution of the Reporting Persons' beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Persons." This indicates a strategic shift rather than a direct transaction involving the shares.
Background
Evommune, Inc. operates within the pharmaceutical preparations industry, as classified under SIC 2834. The company is listed on the NYSE under the ticker symbol EVMN. Recent filings include a 10-Q and an 8-K, indicating ongoing financial and operational updates.
What the Filing Says
The Schedule 13D/A filing states that the reporting persons' ownership includes 2,710,293 shares of common stock held directly by the RA Capital Healthcare Fund, L.P., and 784,345 shares held by RA Capital Nexus Fund III, L.P. The filing notes, "None of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days." This suggests a period of stability in terms of share transactions despite the reported dilution.
Impact
This dilution may affect the perception of Evommune's stability among investors and stakeholders in the pharmaceutical sector. The reporting persons' significant ownership indicates their ongoing influence in the company's strategic decisions. As RA Capital Management is a notable player in the investment landscape, their actions may impact other investors and analysts monitoring Evommune's performance.
What's Next
The filing does not say what happens next. However, stakeholders will likely be watching for further updates from Evommune regarding its financial health and strategic direction following this dilution.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





